PRI-002
Priavoid has successfully applied to start a Phase I clinical trial with PRI-002, a drug for the causal treatment of Alzheimer’s disease. A Phase II clinical trial is in preparation and is scheduled to start in 2018.
News & Events:
Priavoid has successfully applied to start a Phase I clinical trial with PRI-002, a drug for the causal treatment of Alzheimer’s disease. A Phase II clinical trial is in preparation and is scheduled to start in 2018.